TCBIO · Insider Trading
Texas Capital Bancshares, Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Every open-market purchase and sale reported by TCBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | John Matthew Scurlock | Chief Financial Officer | Buy | +43 | +$4.45K |
| 2026-06-10 | Anna M Alvarado | Chief Legal Officer | Sell | −3,500 | −$353.32K |
| 2026-06-08 | Rob C Holmes | Chairman, President and CEO | Sell | −98,600 | −$10.01M |
| 2026-04-29 | Ranjana B Clark | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Steve Rosenberg | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Jonathan Baliff | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Thomas E Long | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Dale W Tremblay | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Mark W Midkiff | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Laura L Whitley | Director | A | +1,092 deriv. | — |
| 2026-04-29 | David S. Huntley | Director | A | +1,092 deriv. | — |
| 2026-04-29 | Paola M Arbour | Director | A | +1,092 deriv. | — |
| 2026-04-23 | Paola M Arbour | Director | M | +1,670 | — |
| 2026-04-23 | Jonathan Baliff | Director | M | +1,670 | — |
| 2026-04-23 | Ranjana B Clark | Director | M | +1,670 | — |
| 2026-04-23 | David S. Huntley | Director | M | +1,670 | — |
| 2026-04-23 | Thomas E Long | Director | M | +1,670 | — |
| 2026-04-23 | Mark W Midkiff | Director | M | +1,670 | — |
| 2026-04-23 | Elysia Holt Ragusa | Director | M | +1,670 | — |
| 2026-04-23 | Steve Rosenberg | Director | M | +1,670 | — |
| 2026-04-23 | Robert W Stallings | Director | M | +1,670 | — |
| 2026-04-23 | Dale W Tremblay | Director | M | +1,670 | — |
| 2026-04-23 | Laura L Whitley | Director | M | +1,670 | — |
| 2026-04-23 | Charles S Hyle | Director | M | +1,670 | — |
| 2026-03-12 | Paola M Arbour | Director | Buy | +1,000 | +$91.50K |
| 2026-03-09 | Robert W Stallings | Director | Buy | +25,500 | +$579.20K |
| 2026-03-05 | Robert W Stallings | Director | Buy | +45,000 | +$1.00M |
| 2026-03-03 | Robert W Stallings | Director | Buy | +28,330 | +$871.73K |
| 2026-02-25 | Robert W Stallings | Director | Buy | +40,000 | +$888.00K |
| 2026-02-23 | Rob C Holmes | Chairman, President and CEO | MIXED | — | −$141.17K |
| 2026-02-19 | Robert W Stallings | Director | Buy | +10,000 | +$221.28K |
| 2026-02-17 | Anna M Alvarado | Chief Legal Officer | MIXED | +773 | −$52.02K |
| 2026-02-17 | John Matthew Scurlock | Chief Financial Officer | MIXED | +1,103 | −$74.05K |
| 2026-02-17 | John W Cummings | Chief Administrative Officer | MIXED | +891 | −$59.88K |
| 2026-02-17 | Rob C Holmes | Chairman, President and CEO | MIXED | +6,026 | −$366.11K |
| 2026-02-10 | Anna M Alvarado | Chief Legal Officer | MIXED | +2,330 | −$159.96K |
| 2026-02-10 | John W Cummings | Chief Administrative Officer | MIXED | +3,361 | −$113.20K |
| 2026-02-10 | John Matthew Scurlock | Chief Financial Officer | MIXED | +2,821 | −$191.66K |
| 2026-02-10 | Ellen Detrich | Controller | MIXED | +983 | −$40.80K |
| 2026-02-10 | Rob C Holmes | Chairman, President and CEO | MIXED | +18,161 | −$1.20M |
| 2026-02-06 | Robert W Stallings | Director | Buy | +16,885 | +$360.58K |
| 2026-02-04 | Robert W Stallings | Director | Buy | +4,115 | +$86.76K |
| 2026-02-02 | Robert W Stallings | Director | Buy | +7,000 | +$146.44K |
| 2026-01-30 | John Matthew Scurlock | Chief Financial Officer | MIXED | +1,553 | −$111.13K |
| 2026-01-30 | David W Oman | Chief Risk Officer | MIXED | +722 | −$57.74K |
| 2026-01-30 | John W Cummings | Chief Administrative Officer | MIXED | +1,057 | −$43.70K |
| 2026-01-30 | Rob C Holmes | Chairman, President and CEO | MIXED | +5,796 | −$422.57K |
| 2026-01-30 | Anna M Alvarado | Chief Legal Officer | MIXED | +652 | −$52.01K |
| 2026-01-27 | Laura L Whitley | Director | Buy | +1,000 | +$97.53K |
| 2026-01-27 | Robert W Stallings | Director | Buy | +2,000 | +$41.82K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert W Stallings | Director | 536,000 | $9.80M |
| Rob C Holmes | Chairman, President and CEO | 435,316 | $7.96M |
| Anna M Alvarado | Chief Legal Officer | 23,810 | $435.25K |
| John Matthew Scurlock | Chief Financial Officer | 22,278 | $407.26K |
| James H Browning | Director | 21,304 | $389.44K |
| Elysia Holt Ragusa | Director | 18,795 | $343.57K |
| Dale W Tremblay | Director | 17,995 | $328.95K |
| Charles S Hyle | Director | 16,020 | $292.85K |
| John W Cummings | Chief Administrative Officer | 13,709 | $250.60K |
| David S. Huntley | Director | 12,468 | $227.92K |
| Thomas E Long | Director | 12,173 | $222.52K |
| Jonathan Baliff | Director | 11,265 | $205.92K |
| Laura L Whitley | Director | 9,631 | $176.05K |
| Ellen Detrich | Controller | 8,855 | $161.87K |
| Paola M Arbour | Director | 8,341 | $152.47K |
| Steve Rosenberg | Director | 7,023 | $128.38K |
| Mark W Midkiff | Director | 2,804 | $51.26K |
| David W Oman | Chief Risk Officer | 2,388 | $43.65K |
| Ranjana B Clark | Director | 1,670 | $30.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.